Home › Non-Small Cell Lung Cancer › Utah › Salt Lake City
Non-Small Cell Lung Cancer clinical trials in Salt Lake City, UT
31 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Salt Lake City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
RecruitingPhase 1/2
- Huntsman Cancer Institute /ID# 271686, Salt Lake City
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
- University of Utah - Huntsman Cancer Institute, Salt Lake City
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RecruitingPhase 3
- Utah Cancer Specialists, Salt Lake City
- Huntsman Cancer Institute, Salt Lake City
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RecruitingPhase 3
- Huntsman Cancer Institute ( Site 0042), Salt Lake City
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Huntsman Cancer Institute, Salt Lake City
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
RecruitingPhase 3
- Local Institution - 0302, Salt Lake City
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
RecruitingPhase 2/3
- Utah Cancer Specialists, Salt Lake City
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RecruitingPhase 1/2
- University of Utah - Huntsman Cancer Institute, Salt Lake City
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RecruitingPhase 3
- Clinical Study Site, Salt Lake City
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RecruitingPhase 1
- Huntsman Cancer Institute, Salt Lake City
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RecruitingObservational study
- Utah Cancer Specialists, Salt Lake City
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RecruitingPhase 1
- Huntsman Cancer Institute, Salt Lake City
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
RecruitingPhase 1/2
- University of Utah - Huntsman Cancer Institute - PPDS, Salt Lake City
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
RecruitingPhase 1
- Huntsman Cancer Institute, Salt Lake City
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RecruitingPhase 1
- Intermountain/LDS Hospital Ph 1 Research Program, Salt Lake City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RecruitingPhase 3
- Huntsman Cancer Institute/University of Utah, Salt Lake City
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
RecruitingPhase 1
- START Mountain Region, Salt Lake City
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecruitingPhase 2
- Huntsman Cancer Institute/University of Utah, Salt Lake City
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RecruitingPhase 1
- Huntsman Cancer Institute, Salt Lake City
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RecruitingPhase 1/2
- Huntsman Cancer Institute, Salt Lake City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2/3
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- Huntsman Cancer Institute/University of Utah, Salt Lake City
Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data
RecruitingObservational study
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Recruiting
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RecruitingPhase 1/2
- Huntsman Cancer Institute, Salt Lake City
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RecruitingPhase 1/2
- University of Utah, Huntsman Cancer Institute, Salt Lake City
PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study
Recruiting
- Huntsman Cancer Institute, Salt Lake City
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RecruitingPhase 1/2
- Utah Cancer Specialists (site 203), Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Salt Lake City
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY121 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH57 studies
- Washington, DC55 studies
Other studies in Salt Lake City
- Cancer (all types)27 studies
- Breast Cancer27 studies
- Colorectal Cancer22 studies
- Lung Cancer21 studies
- Melanoma21 studies
- Multiple Myeloma21 studies
- Metastatic Cancer20 studies
- Ovarian Cancer19 studies
- Obesity18 studies
- Acute Myeloid Leukemia17 studies
- Heart Failure17 studies
- Prostate Cancer15 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.